Sumary of Two-dose regimen of mRNA vaccines provides protection against Alpha and Beta variants in France:
- Over the past six months, the World Health Organization has categorized four SARS-CoV-2 variants as being “of concern” because they are more transmissible or may escape the immune response.
- Scientists from the Institut Pasteur, in collaboration with the French National Health Insurance Fund (CNAM), Ipsos, and Santé Publique France, conducted a nationwide case-control study to evaluate the effectiveness of mRNA vaccines against symptomatic forms of SARS-CoV-2 infection, be that non-variant virus or the Alpha and Beta variants.
- The results of this study were published in The Lancet Regional Health Europe on July 14, 2021. In late 2020, two new variants of SARS-CoV-2 were reported in the United Kingdom and in South Africa, respectively.
- In October 2020, the Institut Pasteur, in collaboration with the French National Health Insurance Fund (CNAM), Ipsos, and Santé Publique France, launched the ComCor study, a case-control study at the national level to analyze the sociodemographic, behavioral, and practical factors associated with SARS-CoV-2 infection.
- The first results of the study were published in The Lancet Regional Health on June 7, 2021 (press release here).
- Arnaud Fontanet, Professor and Head, Epidemiology of Emerging Diseases Unit, Institut Pasteur, Conservatoire National des Arts et Métiers (CNAM).